NeoStem (NBS) Raises Additional Funds Bringing the Total Recent Financings to Over $15 Million

FREE Breaking News Alerts from StreetInsider.com!

More News related to NBS

NeoStem Announces Participation in Two February Conferences
Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Morning Movers 01/20: (INSM) (ASIA) (BVSN) (NBS) Higher; (NCIT) (CCOI) (THS) (ALTH) Lower

More News related to Equity Offerings

July 1, 2009 8:16 AM EDT

NeoStem, Inc. (Amex: NBS) announced that it has raised additional gross funds of over $4 million from institutional and private investors. These funds, together with the $11 million private placement from three Asia-based investors announced April 13, 2009, bring the total investment obtained by NeoStem in the past two and half months to over $15 million. In addition, affiliates of Suzhou Erye Pharmaceuticals Company, Ltd. have increased their overall investment in the Company to over $1,000,000.

As part of its China expansion activities, NeoStem is anticipating, subject to approval of its shareholders, on closing before year end on the acquisition of a 51% interest in Suzhou Erye through a merger with its current 51% owner.